Teva is already marketing our FYB201 ranibizumab biosimilar (Ranivisio/Ongavia) in Europe and can synergistically leverage an existing commercial infrastructure and well-established distribution ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful ...

Teva is already marketing our FYB201 ranibizumab biosimilar (Ranivisio ® /Ongavia ®) in Europe and can synergistically leverage an existing commercial infrastructure..." In return, Klinge will ...

Teva is already marketing our FYB201 ranibizumab biosimilar (Ranivisio /Ongavia ) in Europe and can synergistically leverage an existing commercial infrastructure and well-established distribution ...

1 "We are excited to extend our collaboration with Formycon, reinforcing the solid foundation that commenced with the commercialization of ranibizumab biosimilar (Ranivisio/Ongavia) in Europe. The ...

Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's ...